Many investors are wary of just how much of the new AbbVie's (NYSE:ABBV) revenues are generated by one drug, Humira, and they are concerned what AbbVie will look like once Humira goes off its patent cliff in late 2016. In this video, however, Motley Fool health care bureau chief Brenton Flynn discusses how AbbVie is more than just Humira. Brenton talks about several of the drugs in the company's pipeline -- in spaces like hepatitis C, multiple sclerosis, Parkinson's disease, and endometriosis -- that could slow the revenue fall when Humira's patent expires.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
